Northern Capital Management LLC Has $138,000 Position in Advaxis Inc. (ADXS)
Northern Capital Management LLC held its stake in shares of Advaxis Inc. (NASDAQ:ADXS) during the second quarter, Holdings Channel reports. The fund owned 17,100 shares of the biotechnology company’s stock at the end of the second quarter. Northern Capital Management LLC’s holdings in Advaxis were worth $138,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in shares of Advaxis by 1.2% in the first quarter. Geode Capital Management LLC now owns 183,611 shares of the biotechnology company’s stock valued at $1,658,000 after buying an additional 2,159 shares during the last quarter. Squarepoint Ops LLC boosted its stake in shares of Advaxis by 210.8% in the first quarter. Squarepoint Ops LLC now owns 63,100 shares of the biotechnology company’s stock valued at $570,000 after buying an additional 42,800 shares during the last quarter. Finally, Bank of Montreal Can acquired a new stake in shares of Advaxis during the second quarter valued at approximately $629,000. Hedge funds and other institutional investors own 55.57% of the company’s stock.
Shares of Advaxis Inc. (NASDAQ:ADXS) traded up 10.04% during trading on Tuesday, hitting $12.06. The stock had a trading volume of 1,662,563 shares. The stock has a 50 day moving average price of $11.57 and a 200-day moving average price of $9.68. Advaxis Inc. has a one year low of $5.21 and a one year high of $16.30. The stock’s market capitalization is $480.52 million.
ADXS has been the topic of several research analyst reports. Jefferies Group restated a “buy” rating on shares of Advaxis in a report on Thursday, August 25th. HC Wainwright restated a “buy” rating and set a $23.00 target price on shares of Advaxis in a report on Friday, August 5th. Barclays PLC increased their target price on Advaxis from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, August 3rd. Finally, FBR & Co restated an “outperform” rating and set a $34.00 target price on shares of Advaxis in a report on Thursday, July 7th. Five equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average price target of $24.60.
In related news, Director Richard J. Berman sold 18,000 shares of Advaxis stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $15.21, for a total transaction of $273,780.00. Following the completion of the sale, the director now directly owns 66,430 shares of the company’s stock, valued at approximately $1,010,400.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director David Sidransky sold 22,808 shares of Advaxis stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $15.01, for a total value of $342,348.08. Following the sale, the director now directly owns 91,759 shares of the company’s stock, valued at $1,377,302.59. The disclosure for this sale can be found here. Corporate insiders own 4.56% of the company’s stock.
Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.
Want to see what other hedge funds are holding ADXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Advaxis Inc. (NASDAQ:ADXS).
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.